Dr. Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Zena and Michael A. Wiener Cardiovascular Institute of The Mount Sinai Medical Center. Educated at Columbia University and Boston University School of Medicine, Dr. Halperin joined the Mount Sinai faculty in 1980 and played a key role in the formation of the Cardiovascular Institute, a leading center for integrated cardiovascular research, education and patient care. He is Associate Director of the Institute and Past-President of the Society for Vascular Medicine and the New York City Affiliate of the American Heart Association.
Dr. Halperin was the recipient of the Heart of New York Award for Achievement in Cardiovascular Science and Medicine and the Jacobi Medallion, awarded in recognition of distinguished achievement in the field of medicine at the Mount Sinai Medical Center, as well as several teaching awards. He served on consensus and writing panels that issue clinical practice guidelines for management of patients with various cardiovascular disorders, including atrial fibrillation, peripheral arterial disease, cerebrovascular disease and stroke, was Chair of the ACC/AHA Task Force on Practice Guidelines, Chair of the ACC/AHA/ACP Task Force on Clinical Competence and Training, Co-chair of the ACC Clinical Competence Committee and is currently Deputy Editor of the Journal of the American College of Cardiology.
Dr. Halperin has authored books and journal articles in the field of cardiology and maintained a stream of clinical investigations, beginning with studies of cardiovascular hemodynamics that contributed to the development of angiotensin converting enzyme inhibition for patients with heart failure and studies of regional circulation related to the management of patients with Raynaud’s Disease, mitral valve disease and intermittent claudication. He was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, sponsored by the National Institutes of Health. Clinical evidence from these trials helped to develop antithrombotic strategies to prevent stroke among the millions of Americans with atrial fibrillation. He was Co-Chair of the Executive Steering Committee of the SPORTIF trials, which evaluated the first oral direct thrombin inhibitor for prevention of stroke in patients with atrial fibrillation in 7,000 patients at 700 clinical centers in 25 countries, was a member of the Executive Steering Committee of the ROCKET-AF trial, which doubled the scope to evaluate the first oral factor Xa inhibitor for this indication, and is currently engaged in trials developing improved therapeutic approaches for prevention of morbid events in a wide array of cardiovascular disease states. He has been a member of the ATLAS group since its inception.